International conference on multidisciplinary science

THE USING OF CONCOR AFFECT THE RISK OF ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CORONARY HEART DISEASE

S Mavlonberdiyev

Tashkent Regional Specialized Somatic Hospital

##semicolon## coronary heart disease, myocardial infarction, beta-blockers

सार

During the analysis of data on participants in the REACH registry, results were obtained that indicate that the use of beta-blockers in patients with coronary artery disease, both those who have not had myocardial infarction and those who have had myocardial infarction, as well as in persons without coronary heart disease, but with high risk of developing diseases associated with atherosclerosis is not accompanied by a decrease in the incidence of complications of cardiovascular diseases.

##submission.citations##

1. Bangalore S., Messerli F.H., Cohen J.D., et al; INVEST Investigators. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in pa- tients with prior myocardial infarction: an International Verapamil SR-Trandolapril (INVEST) substudy. Am Heart J 2008;156:241—247.

2. Chen Z.M., Pan H.C., Chen Y.P., et al; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622—1632.

3. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335—371.